title: 90Y-edotreotide for metastatic carcinoid refractory to octreotide.
abstract: OBJECTIVE
  Metastatic carcinoid is an incurable malignancy whose symptoms, such as diarrhea and flushing, can be debilitating and occasionally life-threatening. Although symptom relief is available with octreotide, the disease eventually becomes refractory to octreotide, leaving no proven treatment options. The goal of this study was to evaluate the clinical effect of using (90)Y-edotreotide to treat symptomatic patients with carcinoid tumors.
  
  
  METHODS
  Patients enrolled had metastatic carcinoid, at least one sign/symptom refractory to octreotide, and at least one measurable lesion. Study treatment consisted of three cycles of 4.4 GBq (120 mCi) (90)Y-edotreotide each, once every 6 weeks.
  
  
  RESULTS
  Ninety patients were enrolled in the study. Using Southwest Oncology Group tumor response criteria, 67 (74.%) of 90 patients (95% CI, 65.4% to 83.4%) were objectively stable or responded. A statistically significant linear trend toward improvement was demonstrated across all 12 symptoms assessed. Median progression-free survival was significantly greater (P = .03) for the 38 patients who had durable diarrhea improvement than the 18 patients who did not (18.2 v 7.9 months, respectively). Adverse events (AEs) were reported in 96.7% (87 of 90) of patients. These AEs consisted primarily of reversible GI events (76 of 90), which could be caused in part by concomitant administration of amino acid solution given to reduce radiation exposure to the kidneys. There was one case each of grade 3 oliguria and grade 4 renal failure, each lasting 6 days.
  
  
  CONCLUSIONS
  (90)Y-edotreotide treatment improved symptoms associated with malignant carcinoid among subjects with no treatment alternatives. Treatment was well-tolerated and had an acceptable expected AE profile.
authors.affiliation: Department of Radiology, University of Iowa Roy J. and Lucille A. Carver College of Medicine, 200 Hawkins Dr, Iowa City, IA 52242, USA. david-bushnell@uiowa.edu
authors.forename: David L
authors.initials: DL
authors.lastname: Bushnell
authors.forename: Thomas M
authors.initials: TM
authors.lastname: O'Dorisio
authors.forename: M Sue
authors.initials: MS
authors.lastname: O'Dorisio
authors.forename: Yusuf
authors.initials: Y
authors.lastname: Menda
authors.forename: Rodney J
authors.initials: RJ
authors.lastname: Hicks
authors.forename: Eric
authors.initials: E
authors.lastname: Van Cutsem
authors.forename: Jean-Louis
authors.initials: JL
authors.lastname: Baulieu
authors.forename: Francoise
authors.initials: F
authors.lastname: Borson-Chazot
authors.forename: Lowell
authors.initials: L
authors.lastname: Anthony
authors.forename: Al B
authors.initials: AB
authors.lastname: Benson
authors.forename: Kjell
authors.initials: K
authors.lastname: Oberg
authors.forename: Ashley B
authors.initials: AB
authors.lastname: Grossman
authors.forename: Mary
authors.initials: M
authors.lastname: Connolly
authors.forename: Hakim
authors.initials: H
authors.lastname: Bouterfa
authors.forename: Yong
authors.initials: Y
authors.lastname: Li
authors.forename: Katherine A
authors.initials: KA
authors.lastname: Kacena
authors.forename: Norman
authors.initials: N
authors.lastname: LaFrance
authors.forename: Stanislas A
authors.initials: SA
authors.lastname: Pauwels
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D002276:Carcinoid Tumor / Q000188:drug therapy* / Q000556:secondary*; D018572:Disease-Free Survival; D019008:Drug Resistance, Neoplasm; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D015282:Octreotide / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000627:therapeutic use; D015021:Yttrium Radioisotopes
chemical_list: D015021:Yttrium Radioisotopes; C496730:90Y-octreotide, DOTA-Tyr(3)-; D015282:Octreotide